OpenAI acquires Orchestra Bio to build AI agents that speed up drug development

OpenAI is making a bigger bet on pharmaceuticals. The company acquired Orchestra Bio, a startup that helps pharma teams coordinate drug development. Orchestra will be folded into Rosalind, OpenAI's AI platform for life sciences. GPT-Rosalind helps researchers analyze biological and chemical questions, while Rosalind Workbench connects those capabilities with scientific data and tools.

The combined effort aims to build AI agents that link scientific findings with clinical trials, decisions, and next steps to get new drugs to patients faster. Developing a drug in the US takes ten to 15 years on average. Beyond the scientific hurdles, siloed systems and the constant back-and-forth between internal teams and outside partners slow things down.

Orchestra's agents are designed to take work off teams' plates by tracking trials, flagging affected timelines when something goes wrong like a failed production batch, and surfacing options for what to do next. That could free scientists to focus on decisions and the actual research. OpenAI already works with Novo Nordisk and Moderna on AI-driven pharma research. Financial terms of the deal weren't disclosed.

AI News Without the Hype – Curated by Humans

Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.